Polatuzumab
Aggressive Non-Hodgkin Lymphoma
Lazaros LekakisPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Aggressive Non-Hodgkin Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CYCLOSPORIN A Memorial Sloan Kettering Cancer Center | Phase 3 | BBB |
Vinorelbine Institute of Hematology & Blood Diseases Hospital, China | Phase 3 | BB |
Lipitor University of Minnesota | Phase 2 | BB |
PCV 13 Mayo Clinic | Phase 1/2 | CCC |
Veliparib Northwestern University | Phase 1 | CC |
cb-5339 National Cancer Institute (NCI) | Phase 1 | CC |
Cnty-101 Century Therapeutics, Inc. | Phase 1 | CC |
Same molecule, other indications
Polatuzumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →